Telangiectases in Scleroderma: A Potential Clinical Marker of Pulmonary Arterial Hypertension

REFERENCES

1. 1.↵
   1. Braverman IM,
   2. Ken-Yen A

   . Ultrastructure and three-dimensional reconstruction of several macular and papular telangiectases. Invest Dermatol 1983;81:489–97.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Walker JG,
   2. Stirling J,
   3. Beroukas D,
   4. Dharmapatni K,
   5. Haynes DR,
   6. Smith MD,
   7. et al.

   Histopathological and ultrastructural features of dermal telangiectasias in systemic sclerosis. Pathology 2005;37:220–5.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Wigley FM

   . Vascular disease in scleroderma. Clin Rev Allergy Immunol 2009;36:150–75.

   OpenUrlCrossRefPubMed
4. 4.↵
   Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581–90.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. LeRoy EC,
   2. Black C,
   3. Fleischmajer R,
   4. Jablonska S,
   5. Krieg T,
   6. Medsger TA Jr,
   7. et al.

   Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202–5.

   OpenUrlPubMed
6. 6.↵
   1. Mukerjee D,
   2. St. George D,
   3. Knight C,
   4. Davar J,
   5. Wells AU,
   6. Du Bois RM,
   7. et al.

   Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology 2004;43:461–6.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Joglekar A,
   2. Tsai FS,
   3. McCloskey DA,
   4. Wilson JE,
   5. Seibold JR,
   6. Riley DJ

   . Bosentan in pulmonary arterial hypertension secondary to scleroderma. J Rheumatol 2006;33:61–8.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Hankinson JL,
   2. Odencrantz JR,
   3. Fedan KB

   . Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179–87.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Knudson RJ,
   2. Kaltenborn WT,
   3. Knudson DE,
   4. Burrows B

   . The single-breath carbon monoxide diffusing capacity. Reference equations derived from a healthy nonsmoking population and effects of hematocrit. Am Rev Respir Dis 1987;135:805–11.

   OpenUrlPubMed
10. 10.↵
    1. Robert-Thomson PJ,
    2. Mould TL,
    3. Walker JG,
    4. Smith MD,
    5. Ahern MJ

    . Clinical utility of telangiectasia of hands in scleroderma and other rheumatic disorders. Asian Pac J Allergy Immunol 2002;20:7–12.

    OpenUrlPubMed
11. 11.↵
    1. Kazandjian S,
    2. Bruneval P,
    3. Fiessinger JN,
    4. Camilleri JP,
    5. Housset E

    . Active proliferation of telangiectases in skin of patients with progressive systemic sclerosis (PSS). Arch Dermatol Res 1986;279:8–11.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Shovlin CL,
    2. Guttmacher AE,
    3. Buscarini E,
    4. Faughnan ME,
    5. Hyland RH,
    6. Westermann CJ,
    7. et al.

    Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91:66–7.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Mould TL,
    2. Roberts-Thomson PJ

    . Pathogenesis of telangiectasia in scleroderma. Asian Pac J Allergy Immunol 2000;18:195–200.

    OpenUrlPubMed
14. 14.↵
    1. McAllister KA,
    2. Grogg KM,
    3. Johnson DW,
    4. Gallione CJ,
    5. Baldwin MA,
    6. Jackson CE,
    7. et al.

    Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345–51.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Johnson DW,
    2. Berg JN,
    3. Baldwin MA,
    4. Gallione CJ,
    5. Marondel I,
    6. Yoon SJ,
    7. et al.

    Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996;13:189–95.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Fujimoto M,
    2. Hasegawa M,
    3. Hamaguchi Y,
    4. Komura K,
    5. Matsushita T,
    6. Yanaba K,
    7. et al.

    A clue for telangiectasis in systemic sclerosis: elevated serum soluble endoglin levels in patients with the limited cutaneous form of the disease. Dermatology 2006;213:88–92.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Wipff J,
    2. Kahan A,
    3. Hachulla E,
    4. Sibilia J,
    5. Cabane J,
    6. Meyer O,
    7. et al.

    Association between an endoglin gene polymorphism and systemic sclerosis-related pulmonary arterial hypertension. Rheumatology 2007;46:622–5.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    1. Wipff J,
    2. Avouac J,
    3. Borderie D,
    4. Zerkak D,
    5. Lemarechal H,
    6. Kahan A,
    7. et al.

    Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology 2008;47:972–5.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Dharmapatni AA,
    2. Smith MD,
    3. Ahern MJ,
    4. Simpson A,
    5. Li C,
    6. Kumar S,
    7. et al.

    The TGF beta receptor endoglin in systemic sclerosis. Asian Pac J Allergy Immunol 2001;19:275–82.

    OpenUrlPubMed